Table 2.
Comparison of the clinical findings of the 547 patients at the initiation of GLP1Ra treatment and at the survey
| At the initiation of GLP1Ra treatment | At the survey | P value | |
|---|---|---|---|
| ACR (mg/gCr) [25th-75th percentiles] | 28.0 [11.5, 110.6] | 28.7 [10.9,120.6] | 0.13 |
| Ln ACR | 1.61 ± 0.77 | 1.63 ± 0.79 | 0.54 |
| eGFR (mL/min/1.73 m2) | 73.7 ± 26.4 | 67.1 ± 26.8 | P < 0.001 |
| HbA1c (% [mmol/mol]) | 8.4 ± 1.6 (68 ± 17) |
7.6 ± 1.3 (60 ± 14) |
P < 0.001 |
| BW (kg) | 76.0 ± 19.5 | 73.6 ± 19.5 | P < 0.001 |
| SBP in the office (mmHg) | 132.1 ± 17.0 | 129.3 ± 15.7 | P < 0.001 |
| DBP in the office (mmHg) | 75.8 ± 12.1 | 73.8 ± 11.8 | P < 0.001 |
| MAP in the office (mmHg) | 94.6 ± 12.0 | 92.3 ± 11.5 | <0.001 |
Values are expressed as the mean ± SD or median [25th–75th percentiles].
BW, body weight; DBP, diastolic blood pressure; DPP-4, dipeptidyl peptidase-4; GLP1Ra, glucagon-like peptide-1receptor agonist; LnACR, logarithmic value of urine albumin-to-creatinine ratio; MAP, mean arterial pressure; RAS, renin-angiotensin system; SBP, systolic blood pressure; SGLT2, sodium-glucose co-transporter 2; T2DM, type 2 diabetes mellitus; αGI, alpha-glucosidase inhibitor.